TERN
NASDAQ HealthcareTerns Pharmaceuticals, Inc. - Common Stock
Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
๐ Market Data
| Price | $52.93 |
|---|---|
| Volume | 2,748,428 |
| Market Cap | 6.11B |
| Beta | -0.380 |
| RSI (14-Day) | 78.6 Overbought |
| 200-Day MA | $27.52 |
| 50-Day MA | $48.94 |
| 52-Week High | $53.19 |
| 52-Week Low | $2.65 |
| Forward P/E | -35.97 |
| Price / Book | 5.91 |
๐ฏ Investment Strategy Scores
TERN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (94/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TERN in your text
Paste any article, transcript, or post โ the tool will extract TERN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.